Syntara Limited

Research Syntara Limited (UUDA) on Bullrun: market cap EUR 17.17M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerUUDA
• ExchangeF
• CountryAustralia
• SectorHealthcare
• IndustryDrug Manufacturers - Specialty & Generic
• CurrencyEUR
• Market capEUR 17.17M
• Financial periodFY2025
• Net income-EUR 7.92M
• Free cash flow-EUR 11.12M

Valuation Snapshot

latest market cap is EUR 17.17M.

About Syntara Limited

Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and is in Phase 1c/2 studies for patients with myelodysplastic syndrome.

Frequently asked questions

What is Syntara Limited's market cap?

Syntara Limited's market capitalization is EUR 17.17M.

What does Syntara Limited do?

Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia.